Healthcare: Celgene's Deal – Happy Management Does It Again

<p><span style="font-family: Calibri, Arial, Helvetica, sans-serif; font-size: 16px;">Motley Fool's Michael Douglass and Todd Campbell shed light on how Celgene's deal-making frenzy positions it as a potential MS leader and offer up insight into how to value immuno-oncology stocks.</span></p>